Skip to main content

Advertisement

SpringerLink
Log in

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Yokota S, Kiyoi H, Nakao M, Minami S, Kuriyama K, Takeshita A et al (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia 11:1605–1609

    Article  PubMed  CAS  Google Scholar 

  2. Kottaridis PD, Gale RE, Frew ME, Harrison G, Wheatley K, Groves MJ et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–1759

    Article  PubMed  CAS  Google Scholar 

  3. Thiede C, Steudel C, Mohr B, Schaich M, Schaekel U, Platzbecker U et al (2002) Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326–4335

    Article  PubMed  CAS  Google Scholar 

  4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  PubMed  CAS  Google Scholar 

  5. Zhang W, Konopleva M, Shi YX, Shih YX, McQueen T, Harris D et al (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100:184–198

    Article  PubMed  CAS  Google Scholar 

  6. von Bubnoff N, Engh RA, Aberg E, Saenger J, Peschel C, Duyster J (2009) FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 69:3032–3041

    Article  Google Scholar 

  7. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567–6571

    Article  PubMed  CAS  Google Scholar 

  8. Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A et al (2009) Sorafenib (Nexavar [registered]) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD acute myeloid leukemia. Leuk Res 33:348–350

    Article  PubMed  CAS  Google Scholar 

  9. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F (2008) Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 49:2246–2255

    Article  PubMed  CAS  Google Scholar 

  10. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J et al (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024–2027

    Article  PubMed  CAS  Google Scholar 

  11. White DL, Saunders VA, Dang P, Engler J, Zennettino AC, Cambareri AC et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697–704

    Article  PubMed  CAS  Google Scholar 

  12. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258–264

    Article  PubMed  CAS  Google Scholar 

  13. La Rosée P, Hochhaus A (2010) Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 17:91–96

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/ Oncology, Universitätsklinikum Jena, Erlanger Allee 101, 07740, Jena, Germany

    Sebastian Scholl, Baerbel Spies-Weisshart, Anne Klink, Lars-Olof Muegge, Hans-Joerg Fricke & Andreas Hochhaus

Authors
  1. Sebastian Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baerbel Spies-Weisshart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars-Olof Muegge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans-Joerg Fricke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastian Scholl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scholl, S., Spies-Weisshart, B., Klink, A. et al. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Ann Hematol 90, 473–475 (2011). https://doi.org/10.1007/s00277-010-1027-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1027-9

Keywords

Search

Navigation